You are here

Mitchell Gold

AbbVie beefs up the immunology pipeline, betting up to $865M on a PhII-ready drug — and fueling a biotech stock frenzy

Endpoints

Thu, 06/18/20 - 10:55 am

Alpine Immune Sciences

Former Dendreon CEO debuts new public company in reverse merger

BioPharma Dive

Wed, 04/19/17 - 04:19 pm

Alpine Immune Sciences

Former Dendreon CEO Secures $48M for Cancer Immunotherapy Startup

Forbes

Mon, 06/13/16 - 10:36 am

cancer immunotherapy

Alpine Immune Sciences

Former Dendreon CEO Gold Working on New Cancer Drug Startups

Xconomy

Fri, 10/17/14 - 10:03 am

SEC Probes Former Dendreon CEO Stock Sales

Pharmalot

Tue, 04/30/13 - 09:50 am

Why CEO Replacement Is Good News For Dendreon

Forbes

Wed, 02/1/12 - 11:30 am

The Worst Biotech CEO of 2011 Is ...

TheStreet.com

Fri, 12/9/11 - 10:57 am

Dendreon CEO Dumped $1M in Stock Before Withdrawing Revenue Guidance

BNET Pharma

Thu, 08/4/11 - 01:09 pm